Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 30

1.

Fibroblast Growth Factor Receptor 3 Alterations and Response to PD-1/PD-L1 Blockade in Patients with Metastatic Urothelial Cancer.

Wang L, Gong Y, Saci A, Szabo PM, Martini A, Necchi A, Siefker-Radtke A, Pal S, Plimack ER, Sfakianos JP, Bhardwaj N, Horowitz A, Farkas AM, Mulholland D, Fischer BS, Oh WK, Sharma P, Zhu J, Galsky MD.

Eur Urol. 2019 Nov;76(5):599-603. doi: 10.1016/j.eururo.2019.06.025. Epub 2019 Jul 1.

PMID:
31272788
2.

EMT- and stroma-related gene expression and resistance to PD-1 blockade in urothelial cancer.

Wang L, Saci A, Szabo PM, Chasalow SD, Castillo-Martin M, Domingo-Domenech J, Siefker-Radtke A, Sharma P, Sfakianos JP, Gong Y, Dominguez-Andres A, Oh WK, Mulholland D, Azrilevich A, Hu L, Cordon-Cardo C, Salmon H, Bhardwaj N, Zhu J, Galsky MD.

Nat Commun. 2018 Aug 29;9(1):3503. doi: 10.1038/s41467-018-05992-x.

3.

STK11/LKB1 Mutations and PD-1 Inhibitor Resistance in KRAS-Mutant Lung Adenocarcinoma.

Skoulidis F, Goldberg ME, Greenawalt DM, Hellmann MD, Awad MM, Gainor JF, Schrock AB, Hartmaier RJ, Trabucco SE, Gay L, Ali SM, Elvin JA, Singal G, Ross JS, Fabrizio D, Szabo PM, Chang H, Sasson A, Srinivasan S, Kirov S, Szustakowski J, Vitazka P, Edwards R, Bufill JA, Sharma N, Ou SI, Peled N, Spigel DR, Rizvi H, Aguilar EJ, Carter BW, Erasmus J, Halpenny DF, Plodkowski AJ, Long NM, Nishino M, Denning WL, Galan-Cobo A, Hamdi H, Hirz T, Tong P, Wang J, Rodriguez-Canales J, Villalobos PA, Parra ER, Kalhor N, Sholl LM, Sauter JL, Jungbluth AA, Mino-Kenudson M, Azimi R, Elamin YY, Zhang J, Leonardi GC, Jiang F, Wong KK, Lee JJ, Papadimitrakopoulou VA, Wistuba II, Miller VA, Frampton GM, Wolchok JD, Shaw AT, Jänne PA, Stephens PJ, Rudin CM, Geese WJ, Albacker LA, Heymach JV.

Cancer Discov. 2018 Jul;8(7):822-835. doi: 10.1158/2159-8290.CD-18-0099. Epub 2018 May 17.

4.

Limitations of high throughput methods for miRNA expression profiles in non-functioning pituitary adenomas.

Darvasi O, Szabo PM, Nemeth K, Szabo K, Spisak S, Liko I, Czirjak S, Racz K, Igaz P, Patocs A, Butz H.

Pathol Oncol Res. 2019 Jan;25(1):169-182. doi: 10.1007/s12253-017-0330-3. Epub 2017 Oct 18.

PMID:
29043608
5.

Exosomal MicroRNAs Are Diagnostic Biomarkers and Can Mediate Cell-Cell Communication in Renal Cell Carcinoma.

Butz H, Nofech-Mozes R, Ding Q, Khella HWZ, Szabó PM, Jewett M, Finelli A, Lee J, Ordon M, Stewart R, Krylov S, Yousef GM.

Eur Urol Focus. 2016 Jun;2(2):210-218. doi: 10.1016/j.euf.2015.11.006. Epub 2015 Dec 12.

PMID:
28723537
6.

Neighbours of cancer-related proteins have key influence on pathogenesis and could increase the drug target space for anticancer therapies.

Módos D, Bulusu KC, Fazekas D, Kubisch J, Brooks J, Marczell I, Szabó PM, Vellai T, Csermely P, Lenti K, Bender A, Korcsmáros T.

NPJ Syst Biol Appl. 2017 Jan 24;3:2. doi: 10.1038/s41540-017-0003-6.

7.

MEN1 and microRNAs: The link between sporadic pituitary, parathyroid and adrenocortical tumors?

Nagy Z, Szabó PM, Grolmusz VK, Perge P, Igaz I, Patócs A, Igaz P.

Med Hypotheses. 2017 Feb;99:40-44. doi: 10.1016/j.mehy.2016.12.007. Epub 2016 Dec 19.

PMID:
28110695
8.

Cell cycle dependent RRM2 may serve as proliferation marker and pharmaceutical target in adrenocortical cancer.

Grolmusz VK, Karászi K, Micsik T, Tóth EA, Mészáros K, Karvaly G, Barna G, Szabó PM, Baghy K, Matkó J, Kovalszky I, Tóth M, Rácz K, Igaz P, Patócs A.

Am J Cancer Res. 2016 Sep 1;6(9):2041-2053. eCollection 2016.

9.

Genetic predisposition in patients with hypertension and normal ejection fraction to oxidative stress.

Fazakas Á, Szelényi Z, Szénási G, Nyírő G, Szabó PM, Patócs A, Tegze N, Fekete BC, Molvarec A, Nagy B, Jakus J, Örsi F, Karádi I, Vereckei A.

J Am Soc Hypertens. 2016 Feb;10(2):124-32. doi: 10.1016/j.jash.2015.11.013. Epub 2015 Dec 2.

PMID:
26778769
10.

Overexpression of GRß in colonic mucosal cell line partly reflects altered gene expression in colonic mucosa of patients with inflammatory bowel disease.

Nagy Z, Acs B, Butz H, Feldman K, Marta A, Szabo PM, Baghy K, Pazmany T, Racz K, Liko I, Patocs A.

J Steroid Biochem Mol Biol. 2016 Jan;155(Pt A):76-84. doi: 10.1016/j.jsbmb.2015.10.006. Epub 2015 Oct 22.

PMID:
26480216
11.

miRNA-target network reveals miR-124as a key miRNA contributing to clear cell renal cell carcinoma aggressive behaviour by targeting CAV1 and FLOT1.

Butz H, Szabó PM, Khella HW, Nofech-Mozes R, Patocs A, Yousef GM.

Oncotarget. 2015 May 20;6(14):12543-57.

12.

Randomized Trial of Oral Cyclophosphamide and Veliparib in High-Grade Serous Ovarian, Primary Peritoneal, or Fallopian Tube Cancers, or BRCA-Mutant Ovarian Cancer.

Kummar S, Oza AM, Fleming GF, Sullivan DM, Gandara DR, Naughton MJ, Villalona-Calero MA, Morgan RJ Jr, Szabo PM, Youn A, Chen AP, Ji J, Allen DE, Lih CJ, Mehaffey MG, Walsh WD, McGregor PM 3rd, Steinberg SM, Williams PM, Kinders RJ, Conley BA, Simon RM, Doroshow JH.

Clin Cancer Res. 2015 Apr 1;21(7):1574-82. doi: 10.1158/1078-0432.CCR-14-2565. Epub 2015 Jan 14.

13.

MicroRNAs in adrenal tumors: relevance for pathogenesis, diagnosis, and therapy.

Igaz P, Igaz I, Nagy Z, Nyírő G, Szabó PM, Falus A, Patócs A, Rácz K.

Cell Mol Life Sci. 2015 Feb;72(3):417-428. doi: 10.1007/s00018-014-1752-7. Epub 2014 Oct 9. Review.

PMID:
25297921
14.

Integrative bioinformatics analysis reveals new prognostic biomarkers of clear cell renal cell carcinoma.

Butz H, Szabó PM, Nofech-Mozes R, Rotondo F, Kovacs K, Mirham L, Girgis H, Boles D, Patocs A, Yousef GM.

Clin Chem. 2014 Oct;60(10):1314-26. doi: 10.1373/clinchem.2014.225854. Epub 2014 Aug 19.

15.

Analysis of circulating microRNAs in adrenocortical tumors.

Szabó DR, Luconi M, Szabó PM, Tóth M, Szücs N, Horányi J, Nagy Z, Mannelli M, Patócs A, Rácz K, Igaz P.

Lab Invest. 2014 Mar;94(3):331-9. doi: 10.1038/labinvest.2013.148. Epub 2013 Dec 16.

16.

In silico analysis of pathways affected by differentially expressed microRNA in adrenocortical tumors.

Zsippai A, Szabó PM, Szabó DR, Nagy Z, Patócs A, Rácz K, Igaz P.

J Endocrinol Invest. 2013 Dec;36(11):1011-9. doi: 10.3275/9024. Epub 2013 Jul 1.

PMID:
23812403
17.

Antitumoral effects of 9-cis retinoic acid in adrenocortical cancer.

Szabó DR, Baghy K, Szabó PM, Zsippai A, Marczell I, Nagy Z, Varga V, Éder K, Tóth S, Buzás EI, Falus A, Kovalszky I, Patócs A, Rácz K, Igaz P.

Cell Mol Life Sci. 2014 Mar;71(5):917-32. doi: 10.1007/s00018-013-1408-z. Epub 2013 Jun 27.

PMID:
23807211
18.

Minireview: miRomics in endocrinology: a novel approach for modeling endocrine diseases.

Szabó PM, Butz H, Igaz P, Rácz K, Hunyady L, Patócs A.

Mol Endocrinol. 2013 Apr;27(4):573-85. doi: 10.1210/me.2012-1220. Epub 2013 Jan 24. Review.

19.

Integrative analysis of neuroblastoma and pheochromocytoma genomics data.

Szabó PM, Pintér M, Szabó DR, Zsippai A, Patócs A, Falus A, Rácz K, Igaz P.

BMC Med Genomics. 2012 Oct 29;5:48. doi: 10.1186/1755-8794-5-48.

20.

Effects of mitotane on gene expression in the adrenocortical cell line NCI-H295R: a microarray study.

Zsippai A, Szabó DR, Tömböl Z, Szabó PM, Eder K, Pállinger E, Gaillard RC, Patócs A, Tóth S, Falus A, Rácz K, Igaz P.

Pharmacogenomics. 2012 Sep;13(12):1351-61. doi: 10.2217/pgs.12.116.

PMID:
22966885
21.

mRNA and microRNA expression patterns in adrenocortical cancer.

Zsippai A, Szabó DR, Szabó PM, Tömböl Z, Bendes MR, Nagy Z, Rácz K, Igaz P.

Am J Cancer Res. 2011;1(5):618-28. Epub 2011 Apr 25.

22.

MicroRNA-132 targets HB-EGF upon IgE-mediated activation in murine and human mast cells.

Molnár V, Érsek B, Wiener Z, Tömböl Z, Szabó PM, Igaz P, Falus A.

Cell Mol Life Sci. 2012 Mar;69(5):793-808. doi: 10.1007/s00018-011-0786-3. Epub 2011 Aug 19.

PMID:
21853268
23.

Underexpression of C-myc in adrenocortical cancer: a major pathogenic event?

Szabó PM, Rácz K, Igaz P.

Horm Metab Res. 2011 May;43(5):297-9. doi: 10.1055/s-0031-1273762. Epub 2011 Mar 16.

PMID:
21412688
24.

MicroRNA expression profiling in benign (sporadic and hereditary) and recurring adrenal pheochromocytomas.

Tömböl Z, Eder K, Kovács A, Szabó PM, Kulka J, Likó I, Zalatnai A, Rácz G, Tóth M, Patócs A, Falus A, Rácz K, Igaz P.

Mod Pathol. 2010 Dec;23(12):1583-95. doi: 10.1038/modpathol.2010.164. Epub 2010 Sep 3.

25.

[Pathogenesis of adrenocortical cancer].

Szabó D, Zsippai A, Bendes M, Tömböl Z, Szabó PM, Rácz K, Igaz P.

Orv Hetil. 2010 Jul 18;151(29):1163-70. doi: 10.1556/OH.2010.28931. Review. Hungarian.

PMID:
20591784
26.

Differences in MicroRNA expression profiles of adrenocortical tumors--letter.

Tömböl Z, Szabó PM, Patócs A, Rácz K, Igaz P.

Clin Cancer Res. 2010 May 15;16(10):2915; author reply 2915-6. doi: 10.1158/1078-0432.CCR-10-0308. Epub 2010 May 11. No abstract available.

27.

Meta-analysis of adrenocortical tumour genomics data: novel pathogenic pathways revealed.

Szabó PM, Tamási V, Molnár V, Andrásfalvy M, Tömböl Z, Farkas R, Kövesdi K, Patócs A, Tóth M, Szalai C, Falus A, Rácz K, Igaz P.

Oncogene. 2010 May 27;29(21):3163-72. doi: 10.1038/onc.2010.80. Epub 2010 Mar 22.

PMID:
20305693
28.

Differences in the expression of histamine-related genes and proteins in normal human adrenal cortex and adrenocortical tumors.

Szabó PM, Wiener Z, Tömböl Z, Kovács A, Pócza P, Horányi J, Kulka J, Riesz P, Tóth M, Patócs A, Gaillard RC, Falus A, Rácz K, Igaz P.

Virchows Arch. 2009 Aug;455(2):133-42. doi: 10.1007/s00428-009-0807-x. Epub 2009 Jul 1.

PMID:
19568768
29.

Integrative molecular bioinformatics study of human adrenocortical tumors: microRNA, tissue-specific target prediction, and pathway analysis.

Tömböl Z, Szabó PM, Molnár V, Wiener Z, Tölgyesi G, Horányi J, Riesz P, Reismann P, Patócs A, Likó I, Gaillard RC, Falus A, Rácz K, Igaz P.

Endocr Relat Cancer. 2009 Sep;16(3):895-906. doi: 10.1677/ERC-09-0096. Epub 2009 Jun 22.

PMID:
19546168
30.

Steroid biosynthesis inhibitors in the therapy of hypercortisolism: theory and practice.

Igaz P, Tömböl Z, Szabó PM, Likó I, Rácz K.

Curr Med Chem. 2008;15(26):2734-47. Review.

PMID:
18991633

Supplemental Content

Loading ...
Support Center